This product is not clubbable with other items in cart. Please remove this or other items to proceed further.
Products from multiple soldto's are in cart. Only products from single soldto is allowed in cart.
No Items In Cart
Since 1973 West and Daikyo have embarked on a journey of partnership that has been essential to understanding customer challenges and providing solutions. Celebrating 100-years of West this year, it also marks 50-years of partnership with Daikyo. We recently held an engaging team member event with our Daikyo team as part of our ongoing 100th speaker series. It highlighted the importance of this partnership and the continuous strength between the two companies’ symbiotic relationship and mutual goals to bring great value to the offerings and solutions for the customer and ultimately, the patients we jointly serve.
The history of our partnership with Daikyo has grown significantly throughout the years, embarking in 1973 with a Shareholder agreement, to recent years expanding to a larger minority stake, with exclusive rights of distribution of Daikyo products.
Vinod Vilivalam, Ph.D. VP Daikyo Relationship Partner Executive, commented, "Over the years we have strived to build partnership of trust and collaboration, strengthening innovation and knowledge transfer on both sides, and expanding Commercial, Regulatory, Quality and Scientific collaboration, which has led to innovative product offerings and deeper customer support."
Kuni Noto, EVP Daikyo, commented, "West increased its equity stake in Daikyo Seiko, Ltd. Strengthening the commitment to work together to offer solutions for our customers’ challenges. We aim to strengthen our collaborative efforts ever more than before to ensure a stable supply of innovative high-quality products to the markets."
Looking ahead with a passion for our customers, we aim to continue to strengthen our collaborative efforts and solve challenges for customers in the years to come. Click here to learn more about our partner Daikyo Seiko, Ltd.
Take an in-depth look at the science behind containment & delivery ofinjectable medicines in the West Knowledge Center.
Polymeric container systems are not new to the pharmaceutical industry, and their benefits in terms of break resistance, cosmetic quality and dimensional precision have been recognized by many companies around the world who have chosen to use a polymer vial or syringe.
<p>Demand is increasing for Daikyo’s sterile, ready to use closure components, known as Daikyo RUV® (Ready to Use Validated) components. Against that background, Daikyo has significantly expanded its packaging component sterilization operations to meet the needs of smaller customers as well as large scale pharmaceutical companies. By adopting an approach that replicates its existing footprint, Daikyo has been able to manage validation risks effectively, while meeting an ambitious timeline for bringing on new autoclave capacity. The result of this expansion is a state-of-the-art facility that triples the company’s previous sterilization capacity.</p>
West is pleased to announce that it will begin distribution of a new Daikyo offering – the DAIKYO PLASCAP® RUV one-step press-fit vial closure solution for serum applications. DAIKYO PLASCAP RUV features an integrated stopper and plastic cap, offered in nested configuration for small-batch filling. The closure system offers an alternative to aluminum seals.
Exposure to light is a concern with numerous medications due to the potential for photodegradation or other chemical reactions during manufacturing, storage, and administration<sup>(1)</sup>. This may result in potency loss, altered efficacy and adverse biological effects. The sensitivity of a drug to a distinct spectral region of light may vary with its chemical structure, photoreactivity, and nature of the dosage form. The photochemical behavior of a drug provides guidance for handling, packaging, and labeling of drug products. The use of the appropriate containers and packaging material can protect the products from the deleterious effects of light.
The global injectable drug market sees an ever-increasing adoption of high-value biologic drug products. More than half of today’s 20 top selling injectables are biologics, and many of them are delivered in a prefilled syringe. Even though glass syringes are predominantly used for primary containment of parenterals, the (bio)pharmaceutical industry continues to cope with certain limitations associated with glass prefilled systems.